Malvern Panalytical Acquired Dimer Instruments
The acquisition integrates high-throughput particle analysis into a broader biopharmaceutical distribution network.
Updated on Oct. 12, 2026 in Biotech
Live Poll
Do you trust that corporate mergers typically lead to better products for the consumer?
Malvern Panalytical has completed the acquisition of Santa Barbara-based Dimer Instruments. The move follows a minority investment made in April 2024 and aims to accelerate innovation in drug development platforms.
Why it matters
This consolidation combines Dimer’s specialized instrumentation with Malvern Panalytical’s global scale to streamline protein stability screening. The partnership is designed to speed up biopharmaceutical workflows by merging research capabilities with established distribution channels.
The Dimer Zetasizer Core platform supports high-density screening using 96-, 384-, and 1536-well plate formats. It integrates dynamic light scattering, static light scattering, and differential scanning fluorimetry into a single high-throughput workflow.
The players
Malvern Panalytical
A scientific instrumentation company specializing in materials and structural analysis that formed through a 2017 merger.
Dimer Instruments
A Santa Barbara-based developer of high-throughput biophysical characterization tools founded by Stephen Minne and Michael Larkin.
The details
The Zetasizer Core platform automates complex biophysical measurements by consolidating three distinct analytical methods into a single microwell plate workflow. Dynamic light scattering measures the size distribution of particles, while static light scattering determines molecular weight. Differential scanning fluorimetry detects protein stability by monitoring fluorescence changes during heat-induced unfolding.
Timeline
Malvern Instruments originated in the late 1960s.
The merger of Malvern Instruments and PANalytical occurred in 2017.
Malvern Panalytical invested in Dimer Instruments in April 2024.
The Zetasizer Core platform launched in September 2026.
The acquisition was announced in October 2026.
The Tech Race
This acquisition marks a strategic expansion of Malvern Panalytical's biopharmaceutical portfolio following its 2017 formation. It directly bolsters the company's competitive standing against other firms specializing in high-throughput protein stability screening.
Biopharmaceutical researchers will gain access to the Zetasizer Core technology through Malvern Panalytical’s existing global distribution network. The integration of these tools into standard laboratory plate workflows is expected to increase the efficiency of drug development testing cycles.
The takeaway
The acquisition centralizes high-throughput biophysical analysis within Malvern Panalytical’s infrastructure. Industry observers should track future product releases that leverage this combined technology stack for expanded protein stability and drug development applications.
Further reading
Learn more about the latest technical developments in the Biotech sector.
Source note: This article includes information reported by Manufacturingchemist.
Live Poll
Do you trust that corporate mergers typically lead to better products for the consumer?
